Allezoe Medical Holdings, Inc.
OTC Bulletin Board : ALZM

March 23, 2011 09:31 ET

Allezoe (ALZM) Announces Organ Transport Systems' Medical Advisory Members

FRISCO, TEXAS--(Marketwire - March 23, 2011) - Allezoe Medical Holdings (OTCBB:ALZM) today announced the additional members of its wholly-owned subsidiary Organ Transport Systems' Medical Advisory Board.

Last week Organ Transport Systems revealed that it is in preparations for clinical trials of its LifeCradle®, beginning with applications of its technology to donor heart preservation. OTS has selected the heart as the first focus of its clinical trials due to the pressing need for heart sharing in light of the prevalence of heart disease and personal experiences of the Founder.

The Medical Advisory Board for Organ Transport Systems includes:

  • Robert L. Kormos, MD, FAHA, FRCS(C), a renowned cardiovascular surgeon who has served in medical society positions including President of the International Society of Heart and Lung Transplantation. Dr. Kormos is the Co-Director of Heart Transplantation and the Director of the Artificial Heart Program at Univ. Pittsburgh Medical Center, as well as the Medical Director of the McGowan Institute for Regenerative Medicine.
  • Mark J. Zucker, MD, JD, FACC, FACP, a leader in heart transplantation since 1987. Dr. Zucker has been an investigator in over 50 pharmaceutical or device trials, an author of over 70 papers and abstracts, several book chapters, and a collaborating investigator in the Jarvik total artificial heart trial, the Thoratec Heartmate trials, and most recently the MicroMed DeBakey axial flow pump trial. He has served on the editorial board as a reviewer for notable journals such as Journal of the American College of Cardiology, American Journal of Cardiology, Transplantation Proceedings and Journal of Clinical & Experimental Cardiology. Dr. Zucker has been recognized repeatedly as one of the Top Doctors in New York as well as New Jersey, the Best Doctors in America, and America's Top Physicians.
  • William C. Roberts, MD, a renowned cardiovascular pathologist and prior chief of pathology at the NIH National Heart, Lung & Blood Institute for nearly 30 years. Dr. Roberts is the Executive Director of the Baylor Heart and Vascular Institute at BUMC in Dallas. He has also been the editor in chief of The American Journal of Cardiology since June 1982. Dr. Roberts has contributed information on many cardiovascular conditions, having published just over 1400 articles, authored or edited 24 books, and lectured in more than 2000 cities (some several times) throughout the world. He is the recipient of a number of awards and honors including the Richard and Hilda Rosenthal Foundation Award from the Council of Cardiology of the American Heart Association and the Public Health Service Commendation Medal, a decoration of the United States Department of Health and Human Services.
  • Phil H. Berry, Jr., MD has served as a member of the US Department of Health and Human Services Advisory Committee on Transplantation. Dr. Berry is Clinical Professor of Orthopedics at UT Southwestern Medical Center, and Chief of Orthopedics at Methodist Medical Center in Dallas. Among his honors, Dr. Berry was the recipient of the Max Cole Leadership Award and the prestigious Benjamin Rush Award from the AMA for outstanding citizen efforts for organ donation.
  • William J. Carl III, PhD is the President of Pittsburgh Theological Seminary, a professor, author, and Ethics Consultant. For years Dr. Carl has consulted several major corporations and medical institutions including Duke University Medical Center and The University of Texas Southwestern Medical School. A sought-after speaker internationally, Dr. Carl is also author of six books, several chapters, over 50 articles and reviews, and is editor of three publications.
  • Robert Rawitscher, MD is a board certified thoracic surgeon, has personally performed over 4500 open heart procedures, and is currently retired. For the past two decades he has led the cardiothoracic surgery program for the Promedica Health System based in Toledo, Ohio, currently the largest integrated health system in the country. Dr. Rawitscher is a graduate of Harvard Medical School, completed his general and thoracic surgical training at the University of Virginia and a fellowship in cardiac surgery at the University of California, San Francisco.

Organ Transport Systems, through its LifeCradle®, aims to directly address the discrepancy between available donor organs and those actually transplanted, by improving the preservation technology. The Medical Advisory Board provides guidance and recommendations for interacting with all the parties of the cardiac transplant community and providing insights into the donor organ procurement process and how the LifeCradle® should fit seamlessly into that process. OTS selected the MAB after evaluating their experience and passion for improving the donor organ procurement process and their willingness to share and be a part of the OTS team. Dr. Bob Kormos says that, "The OTS donor heart preservation technology incorporated in the LifeCradle® is based on very sound scientific research and is the best documented research for any donor heart preservation technology to date."

Organ Transport System's Executive Vice President Dr. Tom Franklin says, "OTS is very fortunate to have access to the experiences and wisdom of internationally renowned, seasoned professionals from the real world of organ transplantation to guide our product development and insertion of the LifeCradle® into the organ procurement and preservation process."

FORWARD LOOKING STATEMENT

This announcement is not an offer to sell any Allezoe ("ALZM") related securities. Offers for any given security are made only through applicable offering circulars and related documents filed with the SEC pursuant to the Securities Act of 1933 or the Securities Exchange Act of 1934. Certain statements contained herein and subsequent oral statements made by and on behalf of ALZM may contain "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and includes, without limitation, statements regarding ALZM's plan of business operations, product research and development activities, anticipated revenues and expenses and potential contractual arrangements and obligations. Also, our management may make forward-looking statements orally to investors, analysts, the media and others. Forward-looking statements express our expectations or predictions of future events or results. They are not guarantees and are subject to many risks and uncertainties. There are a number of factors beyond our control that could cause actual events or results to be significantly different from those described in the forward-looking statements. Any or all of our forward-looking statements in this report or in any other public statements we make may turn out to be wrong. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise.

Contact Information